SurModics's subsidiary licenses nanoparticle technology from PharmaSol
SurModics has announced that its Brookwood Pharmaceuticals subsidiary has licensed lipid nanoparticle technology from PharmaSol of Berlin, Germany.
SurModics, a provider of drug delivery and surface modification technologies, has signed a licensing and development agreement with Roche and Genentech, a wholly-owned member of the Roche Group.